Menopause Treatment Market 2019 - Size, Share, Trends and Dynamics, Demand Scenarios, Technology Developments and Competitive landscape

Menopause Treatment Market Information: By Hormonal Treatment (Estrogen, Progesterone, Combination), Non-Hormonal Treatment (Anti-Depressants, Anti-Anxiety, Anti-Migraine), End-User (Hospitals & Clinics, Academia & Research) - Global Forecast Till 2023

Global Menopause Treatment Market Overview:

All most 85% of women experience menopause at the age of 40, which is normal. However, various complications may arise for post postmenopausal women. Such incidences have increased in recent years, and thereby fuelling the demand for menopause treatment. According to the latest report published Market Research Future (MRFR), the global menopause treatment market is set to surge at 4.2% CAGR between 2017 and 2023. Towards the end of the forecast period, the market is expected to surpass a valuation of USD 3 bn.

Free Sample PDF Available Here!!

Reduction in estrogen production and increase secretion of gonadotropin is a common health issue in women post menopause. This could create cessation or irregularities in menstrual flow and cycle, which may lead to vasomotor symptoms. Among symptoms, hot flash is most common. Apart from hot flash, patient may also experience itchiness, abnormal skin sensation, and burning or tingling on the skin.

There are several types of treatments available for menopause related disorders. The growth of the menopause market can be attributed to various factors, which include rising level of awareness about women health, growing number of healthcare and gynaecology centres and advances in hormonal drugs.

Menopause Treatment Market Analyzed By Competitive Landscape

Some of the leading market participants discussed in MRFR report include Novartis AG, Pfizer, Inc., Emcure Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Novo Nordisk A/S, Eli Lilly and Company, Allergan plc, and Cipla Inc.

Menopause Treatment Market: Segmental Overview

MRFR’s report includes a thorough segmental analysis of the global menopause treatment market based on non-hormonal treatment, hormonal treatment and end user.

By non-hormonal treatment, the market has been segmented into anti-anxiety, anti-depressants, migraine and others. By hormonal treatment, the market has been segmented into progesterone, estrogen, combination of the two (estrogen and progesterone) and others. By end user, the market has been segmented into academic and research, hospitals & clinics and others.

Global Menopause Treatment Market: Regional Segmentation

Regions covered in MRFR’s report include North America, Europe, Latin America, Asia Pacific (APAC) and the Middle East & Africa (MEA). Of these, North America and Latin America collectively account for the standout share of the global menopause treatment market. This is mainly owing to the high healthcare expenditure. Health expenditure in the U.S. accounts for nearly 16% of GDP. Several macro and microeconomic factors can be linked with the incessant growth of the pharmaceutical industry in the region. Moreover, faster penetration of new drugs in countries such as the U.S., Canada, Mexico supports the market growth in North America. The region is home to a large number of pharmaceutical companies, which gives the domestic market an advantage.

Europe follows North America in the pecking order, representing the second largest market for menopause treatment. Presence of world class healthcare infrastructure coupled with favourable reimbursement policies is partly propelling the market in Europe. During the forecast period, the U.K., Germany, and France are expected to make significant contribution the market in terms of revenue.

The menopause treatment market is expected to witness an impressive growth in APAC. China and India are expected two most important investment destination for market players operating APAC. These two countries are undergoing transformation in massive scale in various verticals including healthcare.


Menopause Treatment Industry News

The USFDA has recently approved a new drug Evenity (romosozumab-aqqg) for treating osteoporosis in women with high risk of bone fracture post menopause. The drug can be used in women with medical history of osteoporotic fracture or risks associated with fracture. The drug is touted as a prudent alternative to other non-effective osteoporosis treatment.

Duchesnay, a prominent pharmaceutical company having expertise in women health recently received FDA approval for a supplemental New Drug Application (sNDA) for Osphena (ospemifene). sNDA can be used for treating moderate to severe vaginal dryness.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact Info:
Name: Akash Anand
Email: Send Email
Organization: Market Research Future
Address: WantStats Research and Media Pvt. Ltd. Office No. 528, Amanora Chambers
Phone: 6468459312

Release ID: 88919143